Finance

Lists
Why is URGN down 3.11%?
Dive Deeper
URGN:NASDAQ
Urogen Pharma Ltd
$37.07
-3.11%
(-1.19) 1D
Oct 14, 1:32:26 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for URGN...
Open
$37.96
High
$39.09
Low
$37.07
Mkt. cap
1.81B
Avg. vol.
887.34K
Volume
552.37K
52-wk high
$50.81
52-wk low
$16.36
EPS
-$1.98
Beta
1.57
Shares outstanding
48.88M
No. of employees
300
Open
$37.96
High
$39.09
Low
$37.07
Mkt. cap
1.81B
Avg. vol.
887.34K
Volume
552.37K
52-wk high
$50.81
52-wk low
$16.36
EPS
-$1.98
Beta
1.57
Shares outstanding
48.88M
No. of employees
300
News stories
From web sources and news partners
About Urogen Pharma Ltd
CEO-
Employees300
Founded2004
HeadquartersNew York, New York, United States
SectorBiotechnology
Websiteurogen.com
Analyst ratings
Based on 5 analysts giving stock ratings to URGN in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for URGN in the last 3 months.
Highest
Current $37.07
$75.00 (+102.32%)
Average
$60.20 (+62.40%)
Lowest
$48.00 (+29.48%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$75.00
+102.3%
08/21/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$60.00
+61.9%
08/06/2026
Paul Choi
Goldman Sachs
Hold
Maintained
$48.00
+29.5%
08/05/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$58.00
+56.5%
08/05/2026
Tara Bancroft
TD Cowen
Buy
Reiterated
$60.00
+61.9%
08/05/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$32.00
-13.7%
06/03/2026
Kevin DeGeeter
Ladenburg Thalmann & Co.
Buy
Initiated
$43.00
+16%
05/11/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
$40.00
+7.9%
04/20/2026
Amin Makarem
Jefferies
Buy
Initiated
$40.00
+7.9%
04/09/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
27.48M
37.84M
50.96M
72.46M
Cost of goods sold
3.28M
3.29M
4.14M
6.57M
Cost of revenue
3.28M
3.29M
4.14M
6.57M
Research and development expenses
14.01M
14.31M
15.60M
17.34M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
37.58M
39.35M
51.49M
48.44M
Operating expense
51.59M
53.66M
67.08M
65.77M
Total operating expenses
54.87M
56.95M
71.22M
72.34M
Operating income
-27.39M
-19.12M
-20.26M
111.00K
Other non operating income
-4.82M
-4.66M
-4.83M
-4.89M
EBT including unusual items
-34.40M
-26.64M
-28.35M
-8.72M
EBT excluding unusual items
-34.40M
-26.64M
-28.35M
-8.72M
Income tax expense
-1.05M
-275.00K
-4.77M
5.63M
Effective tax rate
3.06%
1.03%
16.83%
-64.54%
Other operating expenses
-
-
-
-
Net income
-33.35M
-26.36M
-23.57M
-14.35M
Net profit margin
-121.34%
-69.68%
-46.26%
-19.81%
Earnings per share
-0.69
-0.53
-0.47
-0.28
Interest and investment income
1.18M
908.00K
931.00K
946.00K
Interest expense
-3.37M
-3.77M
-4.18M
-4.89M
Net interest expenses
-2.20M
-2.86M
-3.25M
-3.94M
Depreciation and amortization charges
-
-
-
-
EBITDA
-27.31M
-19.04M
-20.19M
189.00K
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps